<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724486</url>
  </required_header>
  <id_info>
    <org_study_id>Ph-CT-4301</org_study_id>
    <nct_id>NCT04724486</nct_id>
  </id_info>
  <brief_title>Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI</brief_title>
  <official_title>Effect of GnRH Agonist (Long Protocol) vs GnRH Antagonist (Flexible Protocol) on Oocyte Morphology During IVF/ICSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damascus University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damascus University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selection of developmentally competent oocytes enhances IVF efficiency. Usually, oocyte&#xD;
      quality is determined based on its nuclear maturation and the presence of specific&#xD;
      cytoplasmic and extracytoplasmic morphologic features. Gonadotropin-releasing hormone&#xD;
      agonists (GnRH Agonists) and gonadotropin-releasing hormone antagonists (GnRH Antagonists)&#xD;
      are used during controlled ovarian stimulation (COS) protocols in order to prevent premature&#xD;
      luteinizing hormone (LH) surge and premature ovulation. However, GnRH receptors are also&#xD;
      expressed in extra-pituitary tissues such as ovary, but it is still unknown whether the type&#xD;
      of GnRH analogues used during COS could affect the oocyte morphology, especially with the&#xD;
      limited and conflicted currently available data. Thus, we are conducting this prospective,&#xD;
      non-randomised, open-label, clinical trial to compare the effects of two pituitary&#xD;
      suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on&#xD;
      oocyte morphology during IVF/ICSI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of oocyte dysmorphisms among the studied groups:</measure>
    <time_frame>Before oocytes microinjection</time_frame>
    <description>Before being subjected to ICSI, the oocytes from both groups will be morphologically analyzed under an inverted microscope; Nikon Eclipse Ti2; in order to detect cytoplasmic and extra-cytoplasmic dysmorphisms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved:</measure>
    <time_frame>Immediately after oocyte retrieval (35±2 hours after hCG administration)</time_frame>
    <description>The oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration 35±2 hours after hCG administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Metaphase II Oocytes (MII):</measure>
    <time_frame>Within two hours after oocyte retrieval</time_frame>
    <description>The oocyte maturity will be assessed using Nikon SMZ1500 stereoscope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Metaphase I Oocytes (MI):</measure>
    <time_frame>Within two hours after oocyte retrieval</time_frame>
    <description>The oocyte maturity will be assessed using Nikon SMZ1500 stereoscope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Germinal Vesicle Oocytes (GV):</measure>
    <time_frame>Within two hours after oocyte retrieval</time_frame>
    <description>The oocyte maturity will be assessed using Nikon SMZ1500 stereoscope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Atretic Oocytes:</measure>
    <time_frame>Within two hours after oocyte retrieval</time_frame>
    <description>The oocyte maturity will be assessed using Nikon SMZ1500 stereoscope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maturation Rate%:</measure>
    <time_frame>Within two hours after oocyte retrieval</time_frame>
    <description>Maturation Rate is calculated by dividing the number of mature (MII) oocytes by the number of retrieved oocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization Rate%:</measure>
    <time_frame>16-18 hours after microinjection</time_frame>
    <description>Fertilization Rate is calculated by dividing the number of obtained zygote (2PN) by the number of injected oocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cleavage Rate%:</measure>
    <time_frame>Day 2 after microinjection</time_frame>
    <description>Cleavage rate is calculated by dividing the number of cleavaged embryos by the number of zygotes (2PN).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Quality:</measure>
    <time_frame>Day of transfer (2 or 3 days after microinjection)</time_frame>
    <description>Embryos are assessed using Nikon SMZ1500 stereoscope based on ESHRE criteria (2011).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Quality Embryos rate%:</measure>
    <time_frame>Day of transfer (2 or 3 days after microinjection)</time_frame>
    <description>High Quality Embryos rate is calculated by dividing the number of high quality embryos (Grade I) by the total number of cleavaged embryos.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Pregnancy Rate% (Per Embryo Transfer):</measure>
    <time_frame>2 weeks after embryo transfer</time_frame>
    <description>Biochemical pregnancy is defined as a positive serum beta-hCG pregnancy test after 2 weeks of embryo transfer. The biochemical pregnancy rate is calculated by dividing the number of women who are biochemically pregnant by the number of women who have at least 1 embryo transferred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate% (Per Embryo Transfer):</measure>
    <time_frame>3-4 weeks after embryo transfer</time_frame>
    <description>Clinical pregnancy is defined as the presence of a gestational sac on ultrasound after 3-4 weeks of embryo transfer. The clinical pregnancy rate is calculated as by dividing the number of women who are clinically pregnant divided by the number of women who have at least 1 embryo transferred.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>In Vitro Fertilization</condition>
  <condition>Intracytoplasmic Sperm Injection</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Agonist Group (Long protocol):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antagonist Group (Flexible protocol):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin acetate</intervention_name>
    <description>0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.</description>
    <arm_group_label>Agonist Group (Long protocol):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrorelix</intervention_name>
    <description>0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.</description>
    <arm_group_label>Antagonist Group (Flexible protocol):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin</intervention_name>
    <description>Dosage adjustment according to the ovarian response.</description>
    <arm_group_label>Agonist Group (Long protocol):</arm_group_label>
    <arm_group_label>Antagonist Group (Flexible protocol):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Chorionic Gonadotropin (hCG)</intervention_name>
    <description>Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.</description>
    <arm_group_label>Agonist Group (Long protocol):</arm_group_label>
    <arm_group_label>Antagonist Group (Flexible protocol):</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women undergoing IVF/ICSI.&#xD;
&#xD;
          -  Age: 18-39 years.&#xD;
&#xD;
          -  Both ovaries present.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 40 years&#xD;
&#xD;
          -  History of three or more previous IVF failures.&#xD;
&#xD;
          -  Patients with hormonal disorders like hyperprolactinemia, thyroid disorders.&#xD;
&#xD;
          -  Patients with Polycystic Ovarian Syndrome.&#xD;
&#xD;
          -  Patients who previously undergo Unilateral Oophorectomy.&#xD;
&#xD;
          -  Patients with chronic diseases: diabetes mellitus, cardiovascular diseases, liver&#xD;
             diseases, kidney diseases.&#xD;
&#xD;
          -  Patients with diseases may affect IVF outcomes: Endometriosis, uterine fibroids,&#xD;
             Hydrosalpinx, Adenomyosis, autoimmune diseases,&#xD;
&#xD;
          -  Cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sally Kadoura, B Pharm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdul Hakim Nattouf, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Professor at Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marwan Alhalabi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Professor at Department of Embryology and Reproductive Medicine, Faculty of Medicine, Damascus University, Damascus, Syria.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally Kadoura, B Pharm, MD</last_name>
    <phone>+963991995326</phone>
    <email>sally.kadoura@damascusuniversity.edu.sy</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdul Hakim Nattouf, MD, PhD</last_name>
    <phone>+963933711846</phone>
    <email>abdulhakim.nattouf@damascusuniversity.edu.sy</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orient Hospital</name>
      <address>
        <city>Damascus</city>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marwan Alhalabi, MD, PhD</last_name>
      <phone>+963966400055</phone>
      <email>profalhalabi@icloud.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Syrian Arab Republic</country>
  </location_countries>
  <reference>
    <citation>Aguilar-Rojas A, Huerta-Reyes M. Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells (Review). Oncol Rep. 2009 Nov;22(5):981-90. Review.</citation>
    <PMID>19787210</PMID>
  </reference>
  <reference>
    <citation>Cheung LW, Wong AS. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS J. 2008 Nov;275(22):5479-95. doi: 10.1111/j.1742-4658.2008.06677.x. Review.</citation>
    <PMID>18959738</PMID>
  </reference>
  <reference>
    <citation>Setti AS, Figueira RC, de Almeida Ferreira Braga DP, Azevedo MC, Iaconelli A Jr, Borges E Jr. Oocytes with smooth endoplasmic reticulum clusters originate blastocysts with impaired implantation potential. Fertil Steril. 2016 Dec;106(7):1718-1724. doi: 10.1016/j.fertnstert.2016.09.006. Epub 2016 Oct 12.</citation>
    <PMID>27743693</PMID>
  </reference>
  <reference>
    <citation>Sfontouris IA, Lainas GT, Lainas TG, Faros E, Banti M, Kardara K, Anagnostopoulou K, Kontos H, Petsas GK, Kolibianakis EM. Complex chromosomal aberrations in a fetus originating from oocytes with smooth endoplasmic reticulum (SER) aggregates. Syst Biol Reprod Med. 2018 Aug;64(4):283-290. doi: 10.1080/19396368.2018.1466375. Epub 2018 May 2.</citation>
    <PMID>29718716</PMID>
  </reference>
  <reference>
    <citation>Stigliani S, Moretti S, Casciano I, Canepa P, Remorgida V, Anserini P, Scaruffi P. Presence of aggregates of smooth endoplasmic reticulum in MII oocytes affects oocyte competence: molecular-based evidence. Mol Hum Reprod. 2018 Jun 1;24(6):310-317. doi: 10.1093/molehr/gay018.</citation>
    <PMID>29635518</PMID>
  </reference>
  <reference>
    <citation>Setti AS, Figueira RC, Braga DP, Colturato SS, Iaconelli A Jr, Borges E Jr. Relationship between oocyte abnormal morphology and intracytoplasmic sperm injection outcomes: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2011 Dec;159(2):364-70. doi: 10.1016/j.ejogrb.2011.07.031. Epub 2011 Aug 6. Review.</citation>
    <PMID>21824710</PMID>
  </reference>
  <reference>
    <citation>Lazzaroni-Tealdi E, Barad DH, Albertini DF, Yu Y, Kushnir VA, Russell H, Wu YG, Gleicher N. Oocyte Scoring Enhances Embryo-Scoring in Predicting Pregnancy Chances with IVF Where It Counts Most. PLoS One. 2015 Dec 2;10(12):e0143632. doi: 10.1371/journal.pone.0143632. eCollection 2015.</citation>
    <PMID>26630267</PMID>
  </reference>
  <reference>
    <citation>Cota AM, Oliveira JB, Petersen CG, Mauri AL, Massaro FC, Silva LF, Nicoletti A, Cavagna M, Baruffi RL, Franco JG Jr. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reprod Biol Endocrinol. 2012 Apr 27;10:33. doi: 10.1186/1477-7827-10-33.</citation>
    <PMID>22540993</PMID>
  </reference>
  <reference>
    <citation>Zanetti BF, Braga DPAF, Setti AS, Iaconelli A Jr, Borges E Jr. Effect of GnRH analogues for pituitary suppression on oocyte morphology in repeated ovarian stimulation cycles. JBRA Assist Reprod. 2020 Jan 30;24(1):24-29. doi: 10.5935/1518-0557.20190050.</citation>
    <PMID>31436072</PMID>
  </reference>
  <reference>
    <citation>Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011 Jun;26(6):1270-83. doi: 10.1093/humrep/der037. Epub 2011 Apr 18.</citation>
    <PMID>21502182</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GnRH Agonist</keyword>
  <keyword>GnRH Antagonist</keyword>
  <keyword>Oocyte morphology</keyword>
  <keyword>Assisted reproduction technique</keyword>
  <keyword>In Vitro Fertilization</keyword>
  <keyword>Intracytoplasmic sperm injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

